Observational studyNeuromolecular medicine2026
Association of Cathepsin Proteins with Alzheimer's Disease Risk: An Integrated Observational and Genetic Analysis.
Observational study in Neuromolecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Alzheimer's disease (AD) involves complex lysosomal proteolytic dysfunction, but the specific roles of cathepsin family proteins remain unclear. This study aimed to systematically evaluate the association of cathepsins with AD risk and to explore underlying mechanistic pathways integrating neuroimaging, cognitive, and genetic evidence. We analyzed data from 52,988 UK Biobank participants. Plasma levels of 11 cathepsins were measured via Olink proteomics. Associations with AD diagnosis, cognitive performance, and brain structural measures were assessed using multivariable regression. Mediation analysis tested pathways through cognition and brain structure. Bidirectional two-sample Mendelian randomization (MR) was used to assess potential directional associations, and colocalization analysis was performed to identify shared genetic signals. Among the cathepsins analyzed, CTSL was the most coherent signal across observational analyses, showing associations with AD diagnosis, poorer cognitive performance, and reduced volume in AD-vulnerable regions including the hippocampus. Exploratory mediation analyses identified indirect associational patterns involving cognition and brain structure. Bidirectional MR provided genetic evidence for a positive directional association of genetically predicted CTSL with AD diagnosis (β = 1.2666 on the log-odds scale, p < 0.001) and for a reverse association of AD liability with higher CTSL levels (β = 0.5556, p < 0.001). Colocalization initially suggested a shared signal in the APOE/ZNF285 region, but this signal was not independent of APOE after sensitivity analysis. CTSL emerged as a candidate plasma molecule associated with AD across observational and genetic analyses. These findings support further longitudinal and experimental evaluation of CTSL, while the mechanistic interpretation remains preliminary.
Indexed as
Identifiers
42315799What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.